Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HND026
- Development stage
- Preclinical
- Lead developer
- Handa Pharmaceuticals
- Modality
- Small Molecules
01
Overview
HND026 is a small molecule generic drug candidate being developed by Handa Pharma (formerly Handa Neuroscience) for the treatment of unspecified gastrointestinal disorders. Classified as a "High Barrier Generic," the candidate is currently in the prototype development stage. High-barrier generics typically involve complex formulations or specialized drug delivery technologies designed to replicate the pharmacokinetic profile of difficult-to-manufacture reference products. While Handa Pharma utilizes proprietary platforms such as Melt-3 and controlled-release technologies, specific details regarding the active pharmaceutical ingredient (API) and the reference drug for HND026 have not been publicly disclosed.
Beyond the preview
Go deeper on HND026.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HND026.